Achromatopsia Overview
Achromatopsia Overview:
- Causes: Mutations in genes such as CNGB3 and CNGA3.
- Symptoms: Extreme light sensitivity, difficulty seeing in bright conditions, reduced visual acuity, and color discrimination issues.
- Living with Achromatopsia: Resources and services are available, including low vision specialists and assistive technologies.
- Genetic Testing: Available to assess risk and provide an accurate diagnosis.
- Treatments and Research: No cure currently, but clinical trials for potential treatments, including gene therapy, are underway.
Gene therapy is emerging as a promising avenue for treating achromatopsia. This innovative approach involves introducing genetic material into a person’s cells to correct defective or missing genes. The US FDA-approved gene therapy Luxturna for RPE65-associated Leber congenital amaurosis (LCA) has demonstrated sustained improvements in visual function. Ongoing clinical trials continue to explore gene therapies for other inherited conditions like achromatopsia, showing promising results.
Retina South Africa plays a crucial role in supporting individuals with achromatopsia by providing resources, raising awareness, and advocating for access to the latest treatments and research.

More Articles
Article title: Nanoscope Optogentic Gene Therapy .
Nanoscope's Therapeutics announced in June the results of an Optogenetic Gene Therapy trial to restore meaningful vision in 11.
Article title: E-News – Volume 50 – April 2023 .
In Retinitis Pigmentosa the photoreceptors degenerate and are eventually no longer able to respond to light. Research in Optogenetics.
Article title: World Patient Safety Day .
On September 17, we celebrate World Patient Safety Day under the theme “Engaging patients for patient safety.” This day.